Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata) on August 9, 2010. The report discloses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and associated compensation.
Material Changes
- Board Expansion: The Board of Directors increased its size to seven (7) directors.
- New Appointment: David V. Smith was appointed to fill the newly created vacancy.
- Committee Assignments: Mr. Smith was appointed to the Audit Committee and the Nominating and Governance Committee.
- Compensation Grant: Mr. Smith received an award of stock options to purchase 5,500 shares of common stock.
- Option Terms: The options vest over three years with an exercise price of $15.11 per share.
- Cash Compensation: Mr. Smith is eligible for cash compensation and expense reimbursement per the company's Director Compensation Policy.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document references a press release (Exhibit 99.1) for further details on the appointment.
Investor Verification Checklist
- Verify the total number of directors on the Board is now seven.
- Confirm the vesting schedule and exercise price ($15.11) of the 5,500 options granted to David V. Smith.
- Review the "Director Compensation Policy" in the most recent Schedule 14A proxy statement (filed April 19, 2010) for details on cash compensation.
- Check the attached press release (Exhibit 99.1) for additional context on the appointment.